Astra Biotech to Debut Cystic Fibrosis Array Test in H2 | GenomeWeb

This story has been updated to include comments from a company official.

By Justin Petrone

Astra Biotech will later this year launch a microarray-based test for the detection of 25 of the most common mutations causing cystic fibrosis in pan-European populations, the firm said this week.

The test is one of a number of array-based diagnostics the Luckenwalde, Germany-based company has in development, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?